he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信道地址
下一页:癫痫幼儿死亡简析
- 2022-05-0220131121养生堂:李勇杰说是腰痛的原因有哪些
- 2022-04-212013年国际抗癫痫联合会抗癫痫药物使用指南
- 2019-04-20老年癫痫病的发病原因
- 有问题,排尿有哪些异常表现?
- Sci Rep:可能参与睾丸生理调节
- 美国FDA关于坏死因子阻滞剂、硫唑嘌呤和/或硫唑嘌呤的安全性更新
- 男人下半身的10个难以形容的隐藏
- 幻灯片:慢性炎
- 【关注】扬子江、联环药业同日获得畅销泌尿系统药,50亿市场掀起波澜
- 「感染病的诊断和治疗」第四届京港感染论坛开幕
- FDA警告消费者不要使用肌肉增生产品
- 男性淋病症状 男性淋病怎么治疗?
- 「聚焦海扶刀」兵不刃血 轻松「切除」肾上腺
- 不孕症已成为世界第三大疾病 听试管婴儿专家!
- 孩子学习困难,注意力不集中,坐不住,怎么了家长要小心多动症!
- 炎症是性病吗?
- Prostate Cancer P D:转移性癌症患者接受姑息治疗的当前趋势和社会障碍研究
- 谁来支付医生责任险?医生还是医院?
- Neurology CP:1例巨细胞动脉炎
- 张海澄,北京大学人民医院:心脏病发作后的该如何保障?
- 精囊炎与不孕和性功能障碍的关系
- 精囊恶性预防 五大保健措施
- 扬子江药业评价信息:同日两品种获批上市!今年,共有86个品种的评价
- 煮螃蟹的方法 这样吃螃蟹味道也不错
- JAAD:紫外线光疗会增加湿疹患者皮肤癌的发病率吗?
- 囊肿会影响男性的生育能力吗?需要治疗吗?
- 少射精会诱发结石吗?
- 叉烧包的馅怎么做 很好吃
- 超声分级精索静脉曲张...
- 女人手里有它,男人喜欢
- 财政部:新型冠状病毒感染肺炎患者个人分担费用实行财政兜底
- 病人女性癫痫病的多钱
- 怎么治疗少年稳定型癫痫病最出色
- 控制癫痫发作不仅靠治疗,日常生活这些事项不注意也会激起!
- 成员国扩展批准优时比抗癫痫药物 Vimpat 用于儿童患者
- 乙肝病毒的传染途径 6种途径成乙肝病毒传染重灾区(2)
- 新型“工具”用于病症患者手术评估
- 异地就医体验升级!我国将进一步扩大手术室费用跨省直接结算试点范围
- 男士癫痫病怎么治疗才能有效
- 为什么癫痫病久治不愈
- 药物治疗癫痫病不宜急于求成
- UCB的Vimpat癫痫新适应症在澳大利亚获批
- 千万别回避婴儿癫痫病症状